Elad Sharon and Colleagues: How a Common Trait Unfairly Excludes Black Patients from Cancer Trials
Elad Sharon, Associated Professor of Medicine at Dana-Farber, shared a post on X:
“Very proud of this effort led by one of our former Dana-Farber fellows, Lauren Merz, on the Duffy null phenotype. Thanks to JAMA Oncology for highlighting! Important to see that many otherwise healthy patients are unfairly being excluded because of an arbitrary number… the National Cancer Institute”
Quoting JAMA Oncology’s post:
“Absolute neutrophil count–based eligibility criteria in cancer trials disproportionately exclude Black patients with the Duffy null phenotype, suggesting the need for Duffy status–specific thresholds to improve trial equity.”
Title: Duffy Null–Associated Absolute Neutrophil Counts and Cancer Clinical Trial Eligibility
Authors: Lauren E. Merz, Yating Wang, Angel Cronin, Elad Sharon, Thomas P. Walsh, Stephen P. Hibbs, Christopher S. Lathan, Andrew Hantel
Read full article here.
Never miss hematology updates with Hemostasis Today.
-
May 22, 2026, 13:25Augustina Isioma Ikusemoro: Why Plasma and RBC Transfusions Follow Different Compatibility Rules
-
May 22, 2026, 13:08Anas Hamad: Thrombosis as Overlooked Clinical Challenge in APL
-
May 22, 2026, 12:29Neema Ngugi: Highlighting 6 Major Types of Anemia
-
May 22, 2026, 12:27Jacinto López Sagaseta: Solving the Structural Puzzle of FVIIa–EPCR Interaction
-
May 22, 2026, 12:25Shehab Mohamed: Exploring the Emerging Link Between JAK2 Mutations and Thoracic Aortic Aneurysms
-
May 22, 2026, 11:52Prakash W. Kamat: Highlighting the Role of Physical Activity in Hemophilia Management
-
May 22, 2026, 11:43Mohamed Hanafy Morsy: Understanding Hemochromatosis – Genetics Made Simple
-
May 22, 2026, 10:23Rucha Patil: Insights from The National Haemophilia Conclave 2026
-
May 22, 2026, 10:11Narat Srivali: New Systematic Review and Meta-Analysis on Glucocorticoid Therapy and The Risk of VTE